Key result
Inhibition of PKM2 phosphorylation with TEPP-46 may improve endothelium-dependent vasodilation dysfunction in Type 2 diabetes by modulating the p-eNOS/NO pathway (P<0.05).
Why the study?
To explore the impact and potential mechanism of phosphorylated PKM2 on endothelium-dependent vasodilation function in high glucose using TEPP-46.
Does TEPP-46 improve endothelium-dependent vasodilation in diabetic models?
Does TEPP-46 improve endothelium-dependent vasodilation in diabetic models?
p-value: p=<0.05
Inhibition of PKM2 phosphorylation may represent a novel therapeutic target for improving endothelium-dependent vasodilation dysfunction in diabetic macroangiopathy.
OBJECTIVES: Endothelium-dependent vasodilation dysfunction is the pathological basis of diabetic macroangiopathy. The utilization and adaptation of endothelial cells to high glucose determine the functional status of endothelial cells. Glycolysis pathway is the major energy source for endothelial cells. Abnormal glycolysis plays an important role in endothelium-dependent vasodilation dysfunction induced by high glucose. Pyruvate kinase isozyme type M2 (PKM2) is one of key enzymes in glycolysis pathway, phosphorylation of PKM2 can reduce the activity of pyruvate kinase and affect the glycolysis process of glucose. TEPP-46 can stabilize PKM2 in its tetramer form, reducing its dimer formation and phosphorylation. Using TEPP-46 as a tool drug to inhibit PKM2 phosphorylation, this study aims to explore the impact and potential mechanism of phosphorylated PKM2 (p-PKM2) on endothelial dependent vasodilation function in high glucose, and to provide a theoretical basis for finding new intervention targets for diabetic macroangiopathy. METHODS: The mice were divided into 3 groups: a wild-type (WT) group (a control group, C57BL/6 mice) and a db/db group (a diabetic group, db/db mice), which were treated with the sodium carboxymethyl cellulose solution (solvent) by gavage once a day, and a TEPP-46 group (a treatment group, db/db mice+TEPP-46), which was gavaged with TEPP-46 (30 mg/kg) and sodium carboxymethyl cellulose solution once a day. After 12 weeks of treatment, the levels of p-PKM2 and PKM2 protein in thoracic aortas, plasma nitric oxide (NO) level and endothelium-dependent vasodilation function of thoracic aortas were detected. High glucose (30 mmol/L) with or without TEPP-46 (10 μmol/L), mannitol incubating human umbilical vein endothelial cells (HUVECs) for 72 hours, respectively. The level of NO in supernatant, the content of NO in cells, and the levels of p-PKM2 and PKM2 protein were detected. Finally, the effect of TEPP-46 on endothelial nitric oxide synthase (eNOS) phosphorylation was detected at the cellular and animal levels. RESULTS: <0.05). CONCLUSIONS: p-PKM2 may be involved in the process of endothelium-dependent vasodilation dysfunction in Type 2 diabetes by inhibiting p-eNOS (ser1177)/NO pathway.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2023) studied Type 2 diabetes and diabetic macroangiopathy. TEPP-46 vs. Solvent (sodium carboxymethyl cellulose solution) / wild-type mice / untreated cells was evaluated on Endothelium-dependent vasodilation function, NO levels, and p-PKM2/PKM2 protein levels (p=<0.05). Inhibition of PKM2 phosphorylation with TEPP-46 may improve endothelium-dependent vasodilation dysfunction in Type 2 diabetes by modulating the p-eNOS/NO pathway (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: